- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05065983
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine (CHIKV VLP)
A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objectives:
- To assess the induction of anti-CHIKV neutralizing antibody responses following a single adjuvanted dose of PXVX0317 (40 µg CHIKV VLP, alum-adjuvanted) as measured 21 days (Day 22) after vaccination.
- To assess the induction of anti-CHIKV neutralizing antibody responses following a single adjuvanted dose of PXVX0317 as measured 7 days (Day 8), 14 days (Day 15), and 56 days (Day 57) after vaccination.
Secondary Objectives:
1. To assess safety of a single adjuvanted dose of PXVX0317 in healthy adults.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Johnson County ClinTrials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able and willing to provide informed consent voluntarily signed by participant.
- Any gender, 18 to 45 years of age (inclusive).
- Generally healthy, in the opinion of the Investigator, based on medical history, physical examination, and screening laboratory assessments.
Women who are either:
(i). Not of childbearing potential (CBP): pre-menarche, anatomically sterile, or post-menopausal (defined as ≥12 months without menses) or (ii). Meeting all the following criteria: Negative urine pregnancy test at screening visit; and Negative urine pregnancy test immediately prior to dosing at Day 1; and using an acceptable method of contraception (if female of childbearing potential) for the duration of participation, such as: Hormonal contraceptives (e.g., implants, pills, patches) initiated ≥ 30 days prior to dosing or; Intrauterine device (IUD) inserted ≥30 days prior to dosing or; double barrier type of birth control (male condom with female diaphragm, male condom with cervical cap).
Exclusion Criteria:
- Currently pregnant, breastfeeding, or planning to become pregnant during the study.
- Body Mass Index (BMI) ≥35 kg/m2.
- Positive laboratory evidence of current infection with human immunodeficiency virus (HIV-1, HIV-2), hepatitis C virus (HCV) or hepatitis B virus (HBV).
- History of severe allergic reaction or anaphylaxis to any component of the investigational product (IP).
- History of known congenital or acquired immunodeficiency that could impact response to vaccination (e.g., leukemia, lymphoma, generalized malignancy, functional or anatomic asplenia, alcoholic cirrhosis).
- Prior or anticipated receipt of immunomodulatory or immunosuppressive therapy from six months prior to screening through Day 64.
- Receipt or anticipated receipt of blood or blood-derived products from 90 days prior to screening through Day 64.
- Acute disease within the last 14 days (participants with an acute mild febrile illness can be considered for a deferral of vaccination two weeks after the illness has resolved and treatment has been completed).
- Clinically significant cardiac, pulmonary, respiratory, rheumatologic, or other chronic disease, in the opinion of the Investigator. This may include chronic illness requiring hospitalization in the last one month prior to screening.
- Enrollment in an interventional study and/or receipt of another investigational product from 30 days prior to screening through the duration of study participation.
- Receipt or anticipated receipt of any vaccine from 30 days prior to screening through Day 64.
- Prior receipt of an investigational CHIKV vaccine/product.
- Detectable baseline anti-CHIKV IgG antibody as determined by ELISA.
- Any other condition that, in the opinion of the investigator, could adversely impact the participant's participation or the conduct of the study, creates an unacceptable risk to the participant, or may interfere with the conduct of the study or validity of the data.
- Restricted venous access that would prevent the collection of plasma and serum necessary for participation.
- Weight <110 pounds.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PXVX0317 (CHIKV VLP, alum-adjuvanted) vaccine
All study participants will receive the same Investigational Product (40 µg CHIKV VLP, alum-adjuvanted according to the same single dose schedule on Day 1).
|
Adjuvanted formulation includes aluminum hydroxide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GMFI in CHIK ELISA IgG at Days 8, 15, 22, and 57
Time Frame: 56 days post vaccination
|
GMFI in CHIK ELISA IgG from Day 1 to Days 8, 15, 22, and 57
|
56 days post vaccination
|
GMFI in CHIK ELISA IgM at Days 8, 15, 22, and 57
Time Frame: 56 days post vaccination
|
GMFI in CHIK ELISA IgM from Day 1 to Days 8, 15, 22, and 57
|
56 days post vaccination
|
CHIKV SNA (Serum Neutralizing Antibody) Seroresponse Rate at Day 22
Time Frame: 21 days post vaccination
|
CHIKV SNA Seroresponse Rate (Titer >=40) and Associated 95% Confidence Interval (CI) at Day 22
|
21 days post vaccination
|
CHIKV SNA GMT (Geometric Mean Titer) at Day 22
Time Frame: 21 days post vaccination
|
CHIKV SNA GMT and Associated 95% CI at Day 22
|
21 days post vaccination
|
CHIKV SNA Seroresponse Rates at Days 8, 15, and 57
Time Frame: 56 days post vaccination
|
CHIKV SNA Seroresponse Rates with Associated 95% CIs at Days 8, 15, and 57
|
56 days post vaccination
|
CHIKV SNA GMTs at Days 8, 15, and 57
Time Frame: 56 days post vaccination
|
CHIKV SNA GMTs with Associated 95% CIs at Days 8, 15, and 57
|
56 days post vaccination
|
CHIKV ELISA (Enzyme-Linked Immunosorbent Assay) IgG GMTs at Days 8, 15, 22, and 57
Time Frame: 56 days post vaccination
|
CHIKV ELISA IgG GMTs with Associated 95% CIs at Days 8, 15, 22, and 57
|
56 days post vaccination
|
CHIKV ELISA IgM GMTs at Days 8, 15, 22, and 57
Time Frame: 56 days post vaccination
|
CHIKV ELISA IgM GMTs with Associated 95% CIs at Days 8, 15, 22, and 57
|
56 days post vaccination
|
Geometric Mean Fold Increase (GMFI) in CHIK SNA Titers at Days 8, 15, 22, and 57
Time Frame: 56 days post vaccination
|
GMFI in CHIK SNA Titers from Day 1 to Days 8, 15, 22, and 57
|
56 days post vaccination
|
Number and Percentage of Participants With a CHIKV SNA Titer at or Above Threshold Values at Days 8, 15, 22, and 57
Time Frame: 56 days post vaccination
|
Number and Percentage of Participants with a CHIKV SNA Titer ≥15, 40, 60, 80, 100, 160, 640, and 4-fold Rise Over Baseline Thresholds at Days 8, 15, 22, and 57
|
56 days post vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Solicited Adverse Events (AE) Through Day 8
Time Frame: 7 days post vaccination
|
Incidence of Solicited AEs Through Day 8
|
7 days post vaccination
|
Incidence of Unsolicited AEs Through Day 29
Time Frame: 28 days post vaccination
|
Incidence of Unsolicited AEs Through Day 29
|
28 days post vaccination
|
Incidence of Adverse Events of Special Interest (AESI) Through Day 183
Time Frame: 182 days post vaccination
|
Incidence of AESIs Through Day 183
|
182 days post vaccination
|
Incidence of Serious Adverse Events (SAEs) Through Day 183
Time Frame: 182 days post vaccination
|
Incidence of SAEs Through Day 183
|
182 days post vaccination
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Patrick Ajiboye, Emergent BioSolutions
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EBSI-CV-317-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chikungunya Virus
-
Bavarian NordicEmergent BioSolutionsCompleted
-
Valneva Austria GmbHActive, not recruitingChikungunya Virus InfectionUnited States
-
Themis Bioscience GmbHWalter Reed Army Institute of Research (WRAIR)CompletedChikungunya Virus InfectionPuerto Rico
-
National Institutes of Health Clinical Center (CC)CompletedDengue Virus | Zika Virus | Chikungunya Virus InfectionsUnited States
-
University Hospital Center of MartiniqueUnknownInfected by Chikungunya VirusMartinique
-
Bavarian NordicEmergent BioSolutions; Catalyst Clinical Research, LLCCompletedChikungunya VirusUnited States
-
Assistance Publique Hopitaux De MarseilleTerminated
-
Valneva Austria GmbHCompletedChikungunya Virus InfectionUnited States
-
Bavarian NordicEmergent BioSolutionsCompletedChikungunya Virus InfectionUnited States
-
ModernaTX, Inc.Defense Advanced Research Projects AgencyCompletedChikungunya VirusUnited States
Clinical Trials on CHIKV VLP, adjuvanted
-
Bavarian NordicEmergent BioSolutionsCompletedChikungunya Virus InfectionUnited States
-
Bavarian NordicEmergent BioSolutionsCompleted
-
Bavarian NordicEmergent BioSolutions; Catalyst Clinical Research, LLCCompletedChikungunya VirusUnited States
-
MedicagoCompletedRNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract DiseasesCanada
-
Bavarian NordicRecruitingChikungunya Virus InfectionUnited States
-
MedicagoSyneos HealthCompletedRNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract DiseasesCanada
-
Ihsan GURSEL, PhD, Prof.The Scientific and Technological Research Council of Turkey; MonitorCRO; Nobel...Completed
-
NovavaxDepartment of Health and Human ServicesCompletedInfluenza (Pandemic)United States
-
NovavaxDepartment of Health and Human ServicesCompletedInfluenza (Pandemic)United States
-
NovartisNovartis VaccinesCompleted